Description: <b>Limonene</b>, an oil extracted from the peels of citrus fruits. d-Limonene, one of the common terpenes in nature<br>
<p><b>D-limonene</b> — D-limonene is the naturally dominant citrus-peel enantiomer of limonene, a lipophilic monocyclic monoterpene used as a flavoring/fragrance compound and investigated as an oral anticancer or chemopreventive bioactive. It is best classified as a small-molecule dietary monoterpene / terpene phytochemical rather than an approved oncology drug. Standard abbreviations include DL, d-LIM, and sometimes limonene when the D-enantiomer is implied. Its main natural source is citrus peel oil, especially orange peel oil. Its cancer relevance is supported mainly by preclinical studies plus small human pharmacokinetic and breast-tissue biomarker studies, with no established clinical oncology indication.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Disruption of mevalonate-linked prenylation signaling, including Ras/Rho-associated growth and survival signaling.</li>
<li>Mitochondrial apoptosis induction with MMP loss, Bax/Bcl-2 shift, caspase activation, and PARP cleavage.</li>
<li>Cell-cycle suppression, especially reduced cyclin D1 signaling and proliferation arrest in breast-tissue translational studies.</li>
<li>Autophagy-associated stress response that can contribute to apoptosis in some lung and other cancer models.</li>
<li>ROS elevation and antioxidant depletion in cancer cells at active experimental concentrations, with context-dependent cytotoxic redox stress.</li>
<li>Anti-inflammatory signaling modulation, including suppression of NF-κB-linked cytokine pathways.</li>
<li>Anti-angiogenic and anti-metastatic effects, including VEGF-linked effects in selected models.</li>
<li>Chemosensitization in selected models, including reported enhancement of docetaxel or tamoxifen cytotoxicity.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> D-limonene is orally bioavailable but highly lipophilic and extensively metabolized, with perillic acid and dihydroperillic acid among major human metabolites. Human oncology dosing has required gram-scale exposure; a phase I study reported an oral MTD of 8 g/m2/day with gastrointestinal dose-limiting toxicity. Peak plasma concentration (Cmax) for D-limonene ranged from 10.8+/-6.7 to 20.5+/-11.2 microM. Breast-tissue studies show distribution into human breast tissue, supporting local tissue exposure despite limited systemic biomarker effects. 2 g/day oral d-limonene for 2–6 weeks
Breast tissue mean 41.3 µg/g tissue ≈ ~303 µM tissue-equivalent</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer in-vitro studies use concentration ranges that may exceed typical dietary or supplement-level systemic exposure, so direct translation from cell culture is weak unless tissue accumulation or high-dose formulation exposure is demonstrated. Active clinical exposures are more relevant for lipophilic tissue compartments than for plasma-only comparisons. Mechanisms such as cyclin D1 modulation in human breast tissue are more translationally grounded than high-concentration ROS cytotoxicity assays.</p>
<p><b>Clinical evidence status:</b> Small human / early phase. D-limonene has phase I pharmacokinetic data in advanced solid tumors and short presurgical breast cancer biomarker data, but no large RCT evidence and no regulatory approval as an anticancer therapy. Current use should be considered investigational or adjunct-research context only.</p>
<p><b>Fresh orange peel concerns:</b> Eating fresh sweet orange peel can provide dietary D-limonene and polyphenols, but practical concerns include pesticide or wax residues and possible citrus-drug interaction caution in medication users. Risk can be minimized by using fresh organic or unwaxed sweet oranges, washing and scrubbing the peel, using mostly outer zest rather than thick pith, and storing grated peel refrigerated or frozen. Maximize D-limonene : Use fresh zest, frozen zest, or freeze-dried peel powder.</p>
<h3>D-limonene Cancer Mechanism Matrix</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Mevalonate prenylation signaling</td>
<td>Ras/Rho prenylation ↓; proliferation ↓</td>
<td>Likely lower impact at dietary exposure</td>
<td>G</td>
<td>Growth signaling suppression</td>
<td>Mechanistically central for monoterpene anticancer biology; strongest relevance where tumors rely on prenylated small GTPase signaling.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial apoptosis</td>
<td>MMP ↓; Bax ↑; Bcl-2 ↓; caspase-3 ↑; caspase-9 ↑; PARP cleavage ↑</td>
<td>Usually less cytotoxic at comparable non-transformed model exposure</td>
<td>G</td>
<td>Intrinsic apoptosis induction</td>
<td> MMP↓, Bcl-2↓, and Casp3↑ tags; common endpoint across leukemia, colon, lung, and breast cancer models.</td>
</tr>
<tr>
<td>3</td>
<td>Cell-cycle and cyclin D1 signaling</td>
<td>Cyclin D1 ↓; G1 arrest ↑; proliferation ↓</td>
<td>Limited direct normal-cell evidence</td>
<td>G</td>
<td>Proliferation arrest</td>
<td>Human breast-tissue data make this one of the more translationally credible axes.</td>
</tr>
<tr>
<td>4</td>
<td>Autophagy linked apoptosis</td>
<td>Autophagy ↑; apoptosis ↑</td>
<td>Context-dependent</td>
<td>G</td>
<td>Stress-amplified tumor cell death</td>
<td>Autophagy appears pro-death in selected models but should be marked model-dependent because autophagy can also be adaptive.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial ROS increase</td>
<td>ROS ↑; GSH ↓; oxidative stress ↑</td>
<td>Antioxidant protection ↑ in oxidative-injury models</td>
<td>R/G</td>
<td>Redox stress in cancer cells</td>
<td>Useful but concentration-sensitive; cancer-cell ROS findings should not be generalized to all systemic exposures.</td>
</tr>
<tr>
<td>6</td>
<td>NRF2 and antioxidant response</td>
<td>Mixed or insufficiently defined</td>
<td>Antioxidant defense ↑ (context-dependent)</td>
<td>G</td>
<td>Context-dependent cytoprotection</td>
<td>NRF2 is not the core anticancer mechanism for D-limonene; include only when specific studies show NRF2/HO-1 modulation in the model being indexed.</td>
</tr>
<tr>
<td>7</td>
<td>NF-κB inflammatory signaling</td>
<td>NF-κB linked cytokine signaling ↓; inflammatory survival signaling ↓</td>
<td>Inflammatory injury ↓</td>
<td>R/G</td>
<td>Anti-inflammatory modulation</td>
<td>More strongly supported in inflammatory disease models than direct oncology trials, but relevant to tumor-promoting inflammation.</td>
</tr>
<tr>
<td>8</td>
<td>VEGF angiogenesis and metastasis</td>
<td>VEGF signaling ↓; angiogenesis ↓; invasion/metastasis ↓</td>
<td>Potential wound-healing relevance uncertain</td>
<td>G</td>
<td>Anti-angiogenic and anti-invasive effect</td>
<td>Supported mainly by preclinical cancer models and volatile-oil preparations enriched in D-limonene.</td>
</tr>
<tr>
<td>9</td>
<td>Glycolysis and HIF-1α</td>
<td>Not a primary established axis</td>
<td>Not established</td>
<td>G</td>
<td>Secondary or indirect metabolic effect</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Chemosensitization</td>
<td>Docetaxel effect ↑; tamoxifen effect ↑ (model-dependent)</td>
<td>Normal-cell toxicity not consistently increased in available models</td>
<td>G</td>
<td>Adjunct cytotoxicity enhancement</td>
<td>Preclinical adjunct signal only; timing, dose, formulation, and tumor context should be indexed carefully.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Clinical antitumor efficacy unproven</td>
<td>GI intolerance at high oral doses; skin irritation or sensitization possible with concentrated topical exposure</td>
<td>G</td>
<td>Exposure and evidence limitation</td>
<td>Food-flavor GRAS status does not equal oncology-dose safety; clinical data remain small and non-definitive.</td>
</tr>
</tbody>
</table>
<p><b>TSF legend:</b> P: 0–30 min; R: 30 min–3 hr; G: >3 hr</p>